|
Gabriele Fragasso describes for SIIC the most significant aspects of his article describe para SIIC los aspectos relevantes de su artículo Real world indications to ivabradine treatment in chronic systolic heart failure In a carefully managed population of patients with moderate, stable heart failure with reduced ejection fraction (HFrEF), where optimal guidelines directed medical therapy (GDMT) is properly attained, the indication to ivabradine treatment is around 17%. This percentage represents that group of patients who, either do not tolerate beta-blockers or who have an uncontrolled heart rate despite the maximum tolerated dose of beta-blockers. The article was published by El artículo fue publicado por
Principal institution where the research took place Institución principal de la investigación  Authors' Report Crónica del Autor Indicaciones en la Práctica Diaria para el Tratamiento con Ivabradina en la Insuficiencia Cardíaca Sistólica Crónica En una población meticulosamente controlada de enfermos con insuficiencia cardíaca estable moderada, fracción de eyección reducida, y cumplimiento de las recomendaciones de tratamiento médico óptimo, la indicación de ivabradina tiene lugar en alrededor del 17% de los casos. Este porcentaje es representativo del grupo de pacientes que no toleran el tratamiento con betabloqueantes o que tienen control inadecuado de la frecuencia cardíaca, a pesar de utilizar la dosis máxima tolerada de betabloqueantes. Crónica del Autor Imprimir nota Referencias bibliográficas 1. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:875-85, 2010. 2. Fox K, Ford I, Steg PG, Tendera M, Ferrari R; BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo- controlled trial. Lancet 6;372(9641):807-16, 2008. 3. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 18:891-975, 2016. 4. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail 22:659-69, 2016. 5. Tondi L, Fragasso G, Spoladore R, et al. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure. J Cardiovasc Med (Hagerstown) 19(7):351-356, 2018. 6. Spoladore R, Fragasso G, Perseghin G, et al. Beneficial effects of beta-blockers on left ventricular function and cellular energy reserve in patients with heart failure. Fundam Clin Pharmacol 27:455-64, 2013. 7. Fragasso G, Salerno A, Margonato A. Heart rate reduction is probably not the main beneficial mechanism by which beta blockade improves outcome in patients with systolic chronic heart failure. Am J Cardiol 102:506-7, 2008. 8. Maggioni AP, Anker SD, Dahlström U, et al. Heart Failure Association of the ESC. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 15:1173-84, 2013. SIIC System of Assisted Editing (SSEA) / Sistema SIIC de Edición Asistida (SSEA)
The article is strictly related to the following sections of siicsalud El artículo se relaciona estrictamente con las siguientes secciones de siicsalud
Information about the full text Acerca del trabajo completo Real-Life Indications to Ivabradine Treatment for Heart Rate Optimization in Patients with Chronic Systolic Heart Failure siic DB: / siic DB: http://www.siicsalud.com/main/distriprinrel.php |
|||||||||||||||||||||
Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008
